Erices-Leclercq Melanie, Lubig Sabine, Förster Frank, Förster Robert, Baldus Stefan, Rudlowski Christian, Schröder Lars
Department of Breast Cancer, Lutherian Hospital, Ferrenbergstr.24, 51465, Bergisch Gladbach, Germany.
Department of Economical Sciences, University of Applied Sciences, Zwickau, Germany.
J Cancer Res Clin Oncol. 2022 Feb;148(2):441-447. doi: 10.1007/s00432-021-03623-5. Epub 2021 May 15.
1% of all breast cancer cases occur in men. There are significant differences regarding clinical behaviour and genetic profiles between female (FBC) and male breast cancer (MBC). Parameters for decision-making on treatment and prognosis are derived from FBC. Ki67 has a high value as a prognostic and predictive factor in FBC, but accurate Ki67 cut-off points for MBC are missing. In this study, we aimed to evaluate adequate examination methods and reliable cut-off points for Ki67 to assess the highest prognostic value for patient's overall survival (OS).
In this multicentric retrospective study, histological specimens were obtained from 104 male patients who were diagnosed and treated for primary invasive breast cancer. We applied three methods of Ki67 analysis: Tumor average scoring (TA), tumor border scoring (TB) and hot-spot scoring (HS). Calculated Ki67 cut-off points for each method were assessed as a threshold for patients' overall survival (OS).
Ki67 cut-off points were 13.5 for the TA group, 22.5 for the HS group and 17.5 for the TB group. Only Ki67 TA cut-off calculations demonstrated statistical significance (p = 0.04). Ki67 expression analysis of TA showed that more than 90% of patients with low Ki67 levels (< 13.5) were alive after 5-year follow-up.
Our findings demonstrate that determination of Ki67 expression in TA is the most reliable to define a cut-off point with high prognostic value. A Ki67 cut-off point of 13.5 shows highest statistical power to define luminal A subgroup and OS.
所有乳腺癌病例中1%发生在男性身上。女性乳腺癌(FBC)和男性乳腺癌(MBC)在临床行为和基因图谱方面存在显著差异。治疗和预后决策的参数源自FBC。Ki67在FBC中作为预后和预测因素具有很高的价值,但MBC的准确Ki67临界值尚不清楚。在本研究中,我们旨在评估Ki67的适当检测方法和可靠临界值,以评估对患者总生存期(OS)的最高预后价值。
在这项多中心回顾性研究中,从104例被诊断并接受原发性浸润性乳腺癌治疗的男性患者身上获取组织学标本。我们应用了三种Ki67分析方法:肿瘤平均评分(TA)、肿瘤边界评分(TB)和热点评分(HS)。将每种方法计算出的Ki67临界值评估为患者总生存期(OS)的阈值。
TA组的Ki67临界值为13.5,HS组为22.5,TB组为17.5。只有Ki67 TA临界值计算具有统计学意义(p = 0.04)。TA的Ki67表达分析表明,Ki67水平低(< 13.5)的患者中超过90%在5年随访后仍存活。
我们的研究结果表明,TA法测定Ki67表达最可靠,可确定具有高预后价值的临界值。Ki67临界值为13.5时,在定义管腔A型亚组和OS方面具有最高的统计学效力。